Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lee's Pharm In-licenses AMD Treatment from China's TOT Biopharm

publication date: Jan 5, 2017
Lee's Pharm has in-licensed China rights to a clinic-ready treatment for wet age-related macular degeneration developed by TOT Biopharma of Suzhou. TOT has filed an IND with the CFDA for TAB014, an injected VEGF monoclonal antibody. Lee's Pharm, which is headquartered in Hong Kong, will make upfront and milestone payments, plus pay royalties on sales. It will also be responsible for the costs of clinical development, regulatory submissions and commercialization, though no financial details were provided. More details....

Stock Symbol: (HK: 950)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital